We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Cronos Group (CRON - Free Report) closed the most recent trading day at $12.36, moving -0.32% from the previous trading session. This change lagged the S&P 500's 0.97% gain on the day. Elsewhere, the Dow gained 1.09%, while the tech-heavy Nasdaq added 1.08%.
Heading into today, shares of the cannabis company had lost 3.73% over the past month, lagging the Finance sector's loss of 1.97% and the S&P 500's loss of 3.04% in that time.
CRON will be looking to display strength as it nears its next earnings release, which is expected to be April 29, 2019. The company is expected to report EPS of -$0.01, down 200% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $7.46 million, up 487.4% from the prior-year quarter.
Any recent changes to analyst estimates for CRON should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 66.67% lower within the past month. CRON is currently a Zacks Rank #4 (Sell).
Looking at its valuation, CRON is holding a Forward P/E ratio of 248. Its industry sports an average Forward P/E of 9.86, so we one might conclude that CRON is trading at a premium comparatively.
The Financial - Investment Management industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 241, which puts it in the bottom 6% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
Cronos Group (CRON - Free Report) closed the most recent trading day at $12.36, moving -0.32% from the previous trading session. This change lagged the S&P 500's 0.97% gain on the day. Elsewhere, the Dow gained 1.09%, while the tech-heavy Nasdaq added 1.08%.
Heading into today, shares of the cannabis company had lost 3.73% over the past month, lagging the Finance sector's loss of 1.97% and the S&P 500's loss of 3.04% in that time.
CRON will be looking to display strength as it nears its next earnings release, which is expected to be April 29, 2019. The company is expected to report EPS of -$0.01, down 200% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $7.46 million, up 487.4% from the prior-year quarter.
Any recent changes to analyst estimates for CRON should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 66.67% lower within the past month. CRON is currently a Zacks Rank #4 (Sell).
Looking at its valuation, CRON is holding a Forward P/E ratio of 248. Its industry sports an average Forward P/E of 9.86, so we one might conclude that CRON is trading at a premium comparatively.
The Financial - Investment Management industry is part of the Finance sector. This industry currently has a Zacks Industry Rank of 241, which puts it in the bottom 6% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.